Form 4: Spruce Biosciences CFO Vests Equity, Tax Withholding

Spruce Biosciences' President and CFO, Samir M. Gharib, reported the vesting of restricted stock units and subsequent tax-related share withholdings.

Summary

• Samir M. Gharib, President and CFO of Spruce Biosciences, Inc. (SPRB), reported transactions related to his equity holdings.
• On December 15, 2025, 496 restricted stock units (RSUs) from a December 5, 2022 grant vested, resulting in a net issuance of 318 shares after 178 shares were withheld for taxes at a price of $80.67 per share.
• Also on December 15, 2025, 513 restricted stock units (RSUs) from a December 14, 2023 grant vested, resulting in a net issuance of 329 shares after 184 shares were withheld for taxes at a price of $80.67 per share.
• Following these transactions, Gharib's direct beneficial ownership of common stock is 8,263 shares.
• His direct beneficial ownership of derivative securities (RSUs) is 1,027.

Sentiment

Score: 5

Explanation: The filing reports routine, pre-scheduled executive compensation events (RSU vesting and tax withholding). These are neutral events that do not indicate positive or negative operational or financial performance, but rather the execution of an existing compensation plan.

Positives

• Vesting of restricted stock units indicates continued compensation and retention of a key executive.
• The executive's beneficial ownership of common stock remains substantial at 8,263 shares, aligning his interests with shareholders.

Negatives

• Shares were withheld for tax purposes, reducing the net number of shares issued to the executive.

Future Outlook

The filing details routine equity compensation vesting events for a key executive, which are part of a pre-established vesting schedule and do not provide new forward-looking statements or guidance regarding the company's future performance.

Industry Context

This Form 4 filing is a standard disclosure of insider transactions related to executive compensation. It reflects the routine vesting of restricted stock units, a common form of equity compensation in the biotechnology and pharmaceutical industry, designed to align executive interests with long-term shareholder value and retain talent. Such filings are typical and generally do not indicate significant shifts in broader industry trends or competitive landscape.

Comparison to Industry Standards

• The vesting of restricted stock units and subsequent tax withholding is a standard practice for executive compensation across publicly traded companies, particularly in the biotech sector.
• The structure of multi-year vesting schedules (e.g., 4-year vesting with annual installments) is consistent with industry norms for retaining key personnel and incentivizing long-term performance.
• No specific comparable companies or projects are mentioned in the filing to allow for a direct comparative assessment of the results.

Related Party Transactions

• The vesting and subsequent tax withholding of restricted stock units for Samir M. Gharib, an officer of Spruce Biosciences, constitutes a related party transaction as it involves compensation to a key executive.

Stakeholder Impact

• Shareholders: The vesting and issuance of shares to an executive can result in minor dilution, but also aligns management's interests with shareholder value. The tax withholding at $80.67 per share provides a reference point for the company's stock value at the time of the transaction.
• Employees: This filing highlights the company's equity compensation program, which can be a positive for employee morale and retention, especially for other employees with similar RSU grants.

Next Steps

• Future annual vesting installments of the remaining time-based restricted stock units for Samir M. Gharib, subject to his continuous service.

Key Dates

Keywords

Spruce Biosciences, SPRB, Samir Gharib, Form 4, SEC filing, insider transaction, restricted stock units, RSU vesting, equity compensation, CFO, beneficial ownership